항암치료를 받는 악성 뇌종양 환자의 인지기능에 영향을 미치는 요인

Abstract

Purpose: The purpose of this study was to investigate cognitive decline and its affecting factors such as tumor-related indicators and with or without intravenous infusion of vitamin B12 in patients with high-grade brain cancers. Methods:Forty three patients with high-grade brain cancers admitted to the hospital for concurrent chemo-radiotherapy (CCRT) in 2014 were retrospectively analyzed. For comparative analysis, we investigated the factors affecting patients’ cognitive function using Seoul Neuropsychological Screening Battery Dementia version, and tumor-related factors such as grade, size, location, extent of tumor removal, and intravenous infusion of Vitamin B12 . All factors were compared at 6 weeks after CCRT. Results: Patients with cognitive decline were 15 and other patients without cognitive decline were 28 after CCRT. The factors affecting cognitive decline were tumor grade, size, location, extent of tumor removal, and intravenous infusion of Vitamin B12 . and these factors showed significantly different between with and without cognitive decline groups. Conclusion: An early assessment of cognitive decline will be needed to manage patients with high-grade brain cancers. Intravenous infusion of vitamin B12 will be a therapeutic intervention for the management of cognitive decline in patients with high-grade brain cancers.